Low dose naltrexone (LDN) has a strong safety profile based on available clinical evidence. No serious adverse events have been reported in published trials across multiple conditions, and roughly half of users experience no side effects at all. That said, LDN is an off-label use of an FDA-approved drug, and there are specific situations where it carries real risks.
What LDN Is and Why the Dose Matters
Naltrexone was approved by the FDA at doses of 50 mg daily to treat alcohol dependence and block the effects of opioids. Low dose naltrexone uses a fraction of that amount, typically between 0.5 and 4.5 mg per day. At these much smaller doses, the drug behaves differently in the body. Instead of providing sustained blockade of opioid receptors, LDN produces only brief, temporary receptor blockade. This short-lived effect is thought to trigger changes in the body’s own pain-relieving and anti-inflammatory systems.
LDN also appears to calm overactive immune cells in the brain and spinal cord that drive inflammation and pain signaling. These cells release inflammatory chemicals that can make the nervous system hypersensitive. In lab and animal studies, naltrexone reduces this inflammatory activity. Both of these mechanisms remain under investigation in humans, so they should be understood as plausible explanations rather than fully confirmed pathways.
Because LDN is not FDA-approved at these low doses, it is prescribed off-label and typically prepared by compounding pharmacies. This doesn’t mean it’s unsafe, but it does mean large-scale safety trials of the kind required for FDA approval haven’t been completed.
What the Clinical Trials Show
The most reassuring safety data comes from trials in people with fibromyalgia, multiple sclerosis, and Crohn’s disease. In a study of people with multiple sclerosis, 77% of participants reported zero side effects, and no one was hospitalized due to the drug. Fibromyalgia trials reported no moderate or major adverse effects. In Crohn’s disease research, adverse event rates were no higher on LDN than on placebo, suggesting the drug was well tolerated.
Pooled data from controlled trials found no statistically significant differences between LDN and placebo for sleep disturbance, unusual dreams, headache, decreased appetite, nausea, or fatigue. No serious adverse events were reported. A larger retrospective study of real-world patients found that about half experienced some side effect, most commonly nausea and fatigue, but again, nothing serious.
Common Side Effects
The side effects that do occur tend to be mild and often fade as your body adjusts. The most frequently reported are:
- Headache
- Nausea or vomiting
- Joint or muscle pain
Less common side effects include vivid dreams, sleep disturbance, dizziness, diarrhea, constipation, irritability, loss of appetite, and increased thirst. Some people notice cold-like symptoms such as a runny nose, sneezing, or sore throat. These effects are generally mild enough that most people in clinical trials chose to continue taking the medication.
Vivid or unusual dreams are one of the more distinctive side effects people report. Taking LDN in the morning rather than at bedtime can reduce this. Starting at a lower dose (1 to 3 mg) and gradually increasing to 4.5 mg also helps minimize early side effects.
The Opioid Interaction Risk
The most significant safety concern with LDN involves opioid medications. Because naltrexone blocks opioid receptors, combining it with opioid painkillers creates two distinct dangers.
The first is withdrawal. If you’re currently taking any opioid medication, including codeine, oxycodone, morphine, fentanyl, buprenorphine, or methadone, starting LDN can trigger withdrawal symptoms. Medical guidance calls for stopping opioid therapy for at least ten days before beginning naltrexone.
The second risk is less intuitive but potentially more dangerous. Chronic LDN use may increase the number of opioid receptors in your body, making you hypersensitive to opioids if you take them later. In one documented case, a patient on long-term LDN received a single standard dose of oxycodone (5 mg) and became unresponsive, requiring emergency reversal medication and an overnight stay in intensive care. Standard drug interaction tools flag the risk of withdrawal but may miss this hypersensitivity risk, so it’s important that any prescriber or emergency physician knows you’re taking LDN before administering opioid-based pain relief.
This interaction also matters for surgical situations. If you need an operation or emergency procedure where opioid pain management is standard, your care team needs to know about your LDN use and adjust their approach accordingly.
Pregnancy and Breastfeeding
Safety data for LDN during pregnancy is limited, and most prescribers take a cautious approach. For breastfeeding, the picture is clearer. According to the Mayo Clinic, naltrexone crosses into breast milk in very small amounts and does not cause harmful effects in breastfed infants. Breastfeeding while taking naltrexone is considered safe.
Liver Health and Monitoring
Standard-dose naltrexone (50 mg) carries an FDA boxed warning about potential liver toxicity at high doses. At the much lower doses used in LDN therapy, liver damage has not been a reported concern in clinical studies. Still, because the drug is processed by the liver, periodic liver function testing is a reasonable precaution during long-term use, particularly if you have a preexisting liver condition or drink alcohol regularly.
How LDN Is Typically Started
Most prescribers begin LDN at 1 to 3 mg per day and gradually increase to a target of 4.5 mg daily based on how you respond and tolerate the medication. This slow titration reduces the chance of side effects in the first few weeks. The drug is usually taken once daily, either at bedtime or in the morning. Because LDN is not available as a commercial product at these doses, it’s prepared by a compounding pharmacy, which means quality can vary depending on the pharmacy’s standards.
The gradual dose increase also gives you and your prescriber a chance to identify the lowest effective dose. Some people respond well at 1.5 or 3 mg without ever needing to go higher.